Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

1.

Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.

Christie JE, Shering A, Ferguson J, Glen AI.

Br J Psychiatry. 1981 Jan;138:46-50.

PMID:
7023592
[PubMed - indexed for MEDLINE]
2.

Multiple-dose arecoline infusions in Alzheimer's disease.

Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H.

Arch Gen Psychiatry. 1988 Oct;45(10):901-5.

PMID:
3048224
[PubMed - indexed for MEDLINE]
3.

Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.

Jenike MA, Albert MS, Heller H, Gunther J, Goff D.

J Clin Psychiatry. 1990 Jan;51(1):3-7.

PMID:
2403997
[PubMed - indexed for MEDLINE]
4.

Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.

Raffaele KC, Berardi A, Asthana S, Morris P, Haxby JV, Soncrant TT.

Psychopharmacol Bull. 1991;27(3):315-9.

PMID:
1775605
[PubMed - indexed for MEDLINE]
5.

Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.

Davis KL, Mohs RC.

Am J Psychiatry. 1982 Nov;139(11):1421-4.

PMID:
6753611
[PubMed - indexed for MEDLINE]
6.

No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.

Wettstein A.

Ann Neurol. 1983 Feb;13(2):210-2.

PMID:
6830183
[PubMed - indexed for MEDLINE]
7.

Physostigmine effects in Alzheimer's disease: relationship to dementia severity.

Schwartz AS, Kohlstaedt EV.

Life Sci. 1986 Mar 17;38(11):1021-8.

PMID:
3512944
[PubMed - indexed for MEDLINE]
8.

Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.

Beller SA, Overall JE, Swann AC.

Psychopharmacology (Berl). 1985;87(2):147-51.

PMID:
3931138
[PubMed - indexed for MEDLINE]
9.

Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.

Asthana S, Raffaele KC, Berardi A, Greig NH, Haxby JV, Schapiro MB, Soncrant TT.

Alzheimer Dis Assoc Disord. 1995 Winter;9(4):223-32.

PMID:
8749612
[PubMed - indexed for MEDLINE]
10.

Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.

Caltagirone C, Gainotti G, Masullo C.

Int J Neurosci. 1982 May;16(3-4):247-9.

PMID:
7169287
[PubMed - indexed for MEDLINE]
11.

Oral physostigmine and lecithin improve memory in Alzheimer disease.

Thal LJ, Fuld PA, Masur DM, Sharpless NS.

Ann Neurol. 1983 May;13(5):491-6.

PMID:
6347034
[PubMed - indexed for MEDLINE]
12.

Effects of physostigmine and lecithin on memory in Alzheimer disease.

Peters BH, Levin HS.

Ann Neurol. 1979 Sep;6(3):219-21.

PMID:
534419
[PubMed - indexed for MEDLINE]
13.

Physostigmine and its effect on six patients with dementia.

Ashford JW, Soldinger S, Schaeffer J, Cochran L, Jarvik LF.

Am J Psychiatry. 1981 Jun;138(6):829-30. No abstract available.

PMID:
7246817
[PubMed - indexed for MEDLINE]
14.

Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.

Raffaele KC, Berardi A, Morris PP, Asthana S, Haxby JV, Schapiro MB, Rapoport SI, Soncrant TT.

Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(5):643-8.

PMID:
1956992
[PubMed - indexed for MEDLINE]
15.

Measurement of cholinergic drug effects on memory in Alzheimer's disease.

Brinkman SD, Gershon S.

Neurobiol Aging. 1983 Summer;4(2):139-45. Review.

PMID:
6355883
[PubMed - indexed for MEDLINE]
16.

Effects of oral physostigmine in Alzheimer's disease.

Stern Y, Sano M, Mayeux R.

Ann Neurol. 1987 Sep;22(3):306-10.

PMID:
3674795
[PubMed - indexed for MEDLINE]
17.

Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia.

Caltagirone C, Albanese A, Gainotti G, Masullo C.

Int J Neurosci. 1983;18(1-2):143-7.

PMID:
6840979
[PubMed - indexed for MEDLINE]
18.

Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.

Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R.

Clin Neuropharmacol. 1993 Feb;16(1):61-9.

PMID:
8422658
[PubMed - indexed for MEDLINE]
19.

A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.

Mohs RC, Davis KL.

Neurobiol Aging. 1982 Summer;3(2):105-10.

PMID:
6752738
[PubMed - indexed for MEDLINE]
20.

Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT).

Wettstein A, Spiegel R.

Psychopharmacology (Berl). 1984;84(4):572-3.

PMID:
6441959
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk